NL-OMON50120已完成不适用
Assess safety of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers - MABs therapy m.3243A>G mutation carriers
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adult carriers of >40% m.3243A>G mutation in muscle
排除标准
- •- Use of anti-coagulants, anti-thrombotics and other medication influencing
- •coagulation
- •- Have a weekly alcohol intake of >= 35 units (men) or >= 24 units (women)
- •- Current history of drug abuse
- •- Deficient immune system or autoimmune disease
- •- Significant concurrent illness
- •- Ongoing participation in other clinical trials
- •- Major surgery within 4 weeks of the visit
- •- Vaccination within 4 weeks of the visit
- •- Pregnant or lactating women
- •- Psychiatric or other disorders likely to impact on informed consent
- •- Patients unable and/or unwilling to comply with treatment and study
- •instructions
- •- Allergy for contrast fluid
- •- Peripheral signs of ischemia or vasculopathy
- •- Any other factor that in the opinion of the investigator excludes the patient
- •from the study
研究者
相似试验
撤回
不适用
Intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriersmitochondrial myopathymitochondrial muscular disease10028302NL-OMON42959Erasmus MC, Universitair Medisch Centrum Rotterdam5
尚未招募
2 期
Assess effect and safety of intra-arterial autologous mesoangioblasts administration to the upper arm of m.3243A>G mutation carriersNL-OMON55910Medisch Universitair Ziekenhuis Maastricht20
已完成
1 期
MABs Therapy m.3243A>G Mutation CarriersMitochondrial MyopathiesNCT05063721Maastricht University6
终止
1 期
Patient-Derived Stem Cell Therapy for Diabetic Kidney DiseaseDiabetic Kidney DiseaseDiabetic NephropathiesDiabetic Nephropathy Type 2Kidney FailureKidney InsufficiencyChronic Kidney DiseaseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT03840343Mayo Clinic2
尚未招募
不适用
Evaluation of intra-venous mesenchymal stem cells for the treatment of small joint osteoarthritisMusculoskeletal - OsteoarthritisOsteoarthritisACTRN12619000883112Melbourne Stem Cell Centre10